NK1receptor antagonists under investigation for the treatment of affective disorders
Authors:
- 24 April 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 15 (5) , 479-486
Abstract
Substance P-neurokinin-1 (NK1) receptor pathways have been repeatedly implicated in the pathophysiology of affective disorders. Anatomical studies in humans have shown a high expression of NK1 receptors in brain regions that are important for the regulation of affective behaviours and stress responses. A large body of evidence that has been generated from animal experiments indicates that treatment with a selective NK1 receptor antagonist might be effective in the treatment of certain forms of anxiety and depressive disorders. Accordingly, numerous NK1 receptor antagonists have either been synthesised and are under clinical development, or have already been tested in clinical trials. However, the initial encouraging clinical results were followed by repeated demonstrations of a lack of effectiveness, thus disappointment and doubt currently surrounds the idea that these compounds may become effective antidepressants. Research continues and novel molecules may show better pharmacokinetic and pharmacodynamic properties and, therefore, may achieve therapeutic success. Furthermore, NK1 receptor antagonists that are ineffective in the treatment of mood disorders may still prove to be effective in the treatment of anxiety problems.Keywords
This publication has 61 references indexed in Scilit:
- Sustained pharmacological blockade of NK1 substance P receptors causes functional desensitization of dorsal raphe 5‐HT1A autoreceptors in miceJournal of Neurochemistry, 2005
- Species differences in tachykinin receptor distribution: Further evidence that the substance P (NK1) receptor predominates in human brainJournal of Comparative Neurology, 2005
- Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugsPeptides, 2005
- Chronic Stress Decreases the Number of Parvalbumin-Immunoreactive Interneurons in the Hippocampus: Prevention by Treatment with a Substance P Receptor (NK1) AntagonistNeuropsychopharmacology, 2004
- Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the futureExpert Opinion on Investigational Drugs, 2003
- Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic functionProceedings of the National Academy of Sciences, 2001
- Altered nociception, analgesia and aggression in mice lacking the receptor for substance PNature, 1998
- Immunostaining for substance P receptor labels GABAergic cells with distinct termination patterns in the hippocampusJournal of Comparative Neurology, 1997
- Amino-acid Sequence of Substance PNature New Biology, 1971
- An unidentified depressor substance in certain tissue extractsThe Journal of Physiology, 1931